ROCK

Belumosudil mesylate (KD025 mesylate) is a ROCK2 inhibitor with antifibrotic activity, and can be used in chronic graft-versus-host disease research.

AT13148 is an oral-active and ATP-competitive, multi-AGC kinase inhibitor for Akt1/2/3, p70S6K, PKA, and ROCKI/II.

GSK180736A: GRK2 inhibitor (IC50 0.77µM), >100x selectivity vs GRKs, weak at PKA (IC50 30µM), strong vs ROCK1 (IC50 100nM).

Rhodblock 6 is a Rho kinase inhibitor, blocking phosphorylated MRLC localization by targeting ROCK activity.

GKI-1 HCl is a Greatwall (GWL) kinase inhibitor that inhibits hGWLFL and hGWL-KinDom.The inhibitory effect of GKI-1 HCl on ROCK1 is more significant.

CID-5056270 has anticancer activity and can inhibit lung cancer, anal cancer, bladder cancer, cervical cancer, vulvar cancer, penile cancer, Burkitt's lymphoma

GSK-25 maintains good selectivity against a panel of 31 kinases, as well as RSK1 and p70S6K, and a dramatically improved P450 profile.

Fasudil hydrochloride (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.

ROCK-IN-7 (compound 9) serves as a ROCK kinase inhibitor and is utilized in the investigation of ocular conditions, including glaucoma and retinal diseases [1].

Y-33075 dihydrochloride is a selective inhibitor of ROCK(IC50 of 3.6 nM).

CKI-7 is a potent and ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor.

HA-100 is an inhibitor of protein kinase

Neoprzewaquinone A (NEO), an active ingredient of S. miltiorrhiza, inhibits breast cancer cell migration and promotes smooth muscle relaxation by targeting PIM1 and blocking the ROCK2/STAT3 pathway.

Narciclasine (Lycoricidinol), a natural product, modulates the Rho/Rho-kinase/LIM kinase/cofilin signaling pathway, greatly increasing GTPase RhoA activity.

LX-7101 hydrochloride is a potent LIMK and ROCK2 inhibitor with antihypertensive activity, inhibits LIMK1/2, ROCK, PKA, and can be used to study glaucoma.

Afuresertib hydrochloride is an inhibitor of Akt kinase (Kis of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively)

Hydroxyfasudil (Hydroxy-Fasudil) is a ROCK inhibitor(IC50s of 0.73 and 0.72 μM for ROCK1 and ROCK2, respectively).

CRT0066854 HCl inhibits atypical PKCs; IC50: PKCι 132 nM, PKCζ 639 nM, ROCK-II 620 nM.

View and buy Y-27632 dihydrochloride from TargetMol.Y-27632 is a selective inhibitor of ROCKs.Cited in 10 publications.

GSK269962A hydrochloride (GSK 269962 hydrochloride) is a ROCK inhibitor with anti-inflammatory and vasodilatory effects and inhibits ROCK1 and ROCK2.

Netarsudil mesylate (AR-13324 mesylate) is a Rho-related protein kinase inhibitor used to study glaucoma and hypertension.

ROCK2-IN-2 is a selective inhibitor of ROCK2 (IC50 of <1 μM).

Y-33075 (Y-39983 free base) is a ROCK inhibitor that lowers IOP, increases blood flow to ONH, and increases the number of RGCs with regenerating axons.

Netarsudil Dihydrochloride (AR-13324 Dihydrochloride) is an inhibitor of Rho-related protein kinase (ROCK) and norepinephrine transporter (NET) and is effective in reducing intraocular pressure (IOP).Cost-effective and quality-assured.

BDP9066 is a potent and selective MRCK inhibitor, inhibits MRCKβ and MRCKα/β, and can be used for the prevention and treatment of skin cancer.

SB-747651A dihydrochloride, an MSK1 inhibitor (IC50=11 nM), also targets PRK2, RSK1, p70S6K, ROCK-II; potential in inflammation study.

Verosudil (AR-12286), a ROCK1/2 inhibitor (Ki: 2 nM), lowers intraocular pressure in mice by enhancing aqueous outflow.

CCG-222740 is an inhibitor of Rho/MRTF pathway

SAR407899 hydrochloride is a selective, potent and ATP-competitive ROCK inhibitor, with an IC50 of 135 nM for ROCK-2, and Kis of 36 nM and 41 nM for human and

URMC-099: oral, brain-accessible MLK/LRRK2 inhibitor; IC50 - MLK1/2/3/DLK: 19/42/14/150 nM, LRRK2: 11 nM.

ROCK inhibitor-2 is a selective dual inhibitor of ROCK1 and ROCK2 (IC50s of 17 nM and 2 nM, respectively).

ROCK2 inhibitor is a chemical compound associated with the therapeutic management of psoriasis.

GSK269962A (GSK269962A HCl) is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.

BDP5290 is a potent inhibitor of both ROCK and MRCK(IC50s of 5 nM, 50 nM, 10 nM and 100 nM for ROCK1, ROCK2, MRCKα and MRCKβ, respectively.)

ROCK/HDAC-IN-1 (Compound 10h) serves as an orally effective inhibitor of ROCK/HDAC. This compound suppresses ROCK1/2 (IC50: 254.9 nM, 58.18 nM) and HDAC1/2/3/6/8 (IC50: 9.09, 8.03, 6.26, 0.41, 7.69 nM). It stimulates the activation of DAMPs, notably calreticulin (CRT) exposure and HMGB1 release, suggesting its potential as an inducer of immunogenic cell death (ICD). ROCK/HDAC-IN-1 exhibits antiproliferative effects against breast cancer cells (IC50: 0.37 μM for MDA-MB-231 cells), inhibits tumor growth, activates T cells, and shows no significant toxicity.

H-1152 is a potent, specific, ATP-competitive, and cell permeable ROCK inhibitor (Ki = 1.6 nM).

ROCK-IN-9 (Compound T345), a ROCK inhibitor, exhibits cytotoxicity in HepG2 cells with an IC50 of 40.8 μM.

CAY10746 selectively inhibits ROCK I/II with IC50s: 0.014/0.003 μM, useful for diabetic retinopathy research.

ROCK2-IN-9 (compound 7u), a selective ROCK2 inhibitor with an IC50 value of 36.8 nM, demonstrates anticancer properties by impeding cancer cell migration and invasion. This action is achieved through the regulation of various actin cytoskeleton cellular activities. It holds potential for use in breast cancer research.

ROCK2-IN-6 hydrochloride (Comp A)为一种选择性ROCK2抑制剂,适用于研究ROCK介导的疾病、自身免疫性病症与炎症。

SB-772077B dihydrochloride is an aminofurazan-based Rho kinase inhibitor (IC50s: 5.6 nM and 6 nM toward ROCK1 and ROCK2, respectively).

Chroman 1 is a potent inhibitor of ROCK1 (IC50 = 52 pM) and ROCK2 (IC50 = 1 pM).

RKI1313 (RKI-1313) was a selective inhibitor for ROCK-dependent signaling, cytoskeletal changes, anchorage-independent colony formation, migration, and invasion

Akt/ROCK-IN-1 (B12) is a dual inhibitor targeting Akt and ROCK, exhibiting IC50 values of 0.023 nM and 1.47 nM, respectively.

Y-27632 (Y-27632) is an orally potent, ATP-competitive inhibitor of ROCK-I and ROCK-II.

Tofacitinib (Tasocitinib) is an orally Janus kinase inhibitor. Tofacitinib is used for the treatment of rheumatoid arthritis. Cost effective and quality assured.

PT109 is a multikinase inhibitor that targets JNK and other kinases, playing a crucial role in anti-inflammatory, antioxidative, neurogenic, and synaptogenic processes. Specifically, PT109 inhibits JNK isoforms with the following IC50 values: JNK1 at 0.143 μM, JNK2 at 0.831 μM, and JNK3 at 0.285 μM. It also inhibits SGK isoforms (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM) and ROCK2 (IC50=34 μM). Additionally, PT109 reprograms polymorphic glioblastoma multiforme (GBM) into oligodendroglia via the PTBP1/PKM1/2 pathway and alters the metabolic pattern of GBM to exhibit antiglioma activity.

AS 1892802, a ROCK inhibitor: IC50 - 52nM (hROCK2), 57nM (rROCK2), 122nM (hROCK1). Fast antinociceptive effect similar to Tramadol, Diclofenac.

Fasudil (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK.

Hydroxyfasudil Hydrochloride (HA 1100 hydrochloride) is a ROCK1/2 inhibitor (IC50s: 0.73/0.72 μM).

Ripasudil free base (K-115 (free base)) is a selective and potent ROCK inhibitor, is a novel and potent antiglaucoma agent.

H-1152 2HCl: ROCK inhibitor, IC50=12 nM, Ki=1.6 nM. Blocks PKA, PKC, PKG, Aurora A, CaMKII with higher IC50s.

Belumosudil (Rezurock) is an orally available, and specific ROCK2 inhibitor (IC50/Ki: 60/41 nM).

CMPD101 is a membrane-permeable small-molecule inhibitor of GRK2/3 (IC50: 18 nM and 5.4 nM).

ROCK-IN-6, a selective ROCK2 inhibitor, exhibits potent inhibition with an IC50 of 2.19 nM and holds promise for research into glaucoma and retinal diseases [1

WAY-656935 inhibits ROCK.

Zelasudil (RXC007) is a Rho-related (ROCK) kinase inhibitor for the study of idiopathic pulmonary fibrosis and inflammation.

Rho-Kinase-IN-1: ROCK inhibitor, Ki of 30.5 nM (ROCK1) & 3.9 nM (ROCK2), used in research for diseases linked to cell overgrowth and inflammation.

ROCK-IN-2 (Azaindole 1) is a selective and ATP-competitive ROCK inhibitor with IC50 of 0.6 and 1.1 nM for human ROCK-1 and ROCK-2.

RKI-1447 is a potent inhibitor of ROCK1 and ROCK2. It has anti-invasive and antitumor activities.

Thiazovivin, a ROCK inhibitor (IC50: 0.5 μM), increases the survival rate of hESC.

SAR407899 is Rho kinase inhibitor potently inhibits endothelin-1-induced constriction of renal resistance arteries.

ROCK-IN-1 is a potent ROCK inhibitor that inhibits ROCK2-mediated signaling with an IC50 value of 1.2 nM.ROCK-IN-1 can be used in the study of neurological

GSK429286A (RHO-15) is a specific inhibitor of ROCK1/2 (IC50: 14/63 nM).

Afuresertib (GSK2110183) is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic